Reset
Id
Protein
PTM type
Site
Species
Disease
Celline
Drug
Regulatory
Confidence score(level)
Ref.
acc2251 RB1 phosphorylation Thr356 human Head and Neck Cancer FaDu Palbociclib Associated 4.0 (Moderate) 26265441
acc2252 RB1 phosphorylation Thr356 human Head and Neck Cancer SCC61 Palbociclib Associated 4.0 (Moderate) 26265441
acc2253 RelA phosphorylation Ser536 human Breast Cancer MCF7 RITA Enhancing 5.0 (High) 27721021
acc2254 RelA phosphorylation Ser276 human Breast Cancer MCF7 RITA Impairing 5.0 (High) 27721021
acc2255 RelA phosphorylation Ser468 human Breast Cancer MCF7 RITA Impairing 5.0 (High) 27721021
acc2256 RelA phosphorylation Ser536 human Colorectal Cancer HCT116 RITA Enhancing 5.0 (High) 27721021
acc2257 RelA phosphorylation Ser276 human Colorectal Cancer HCT116 RITA Impairing 5.0 (High) 27721021
acc2258 RelA phosphorylation Ser468 human Colorectal Cancer HCT116 RITA Impairing 5.0 (High) 27721021
acc2259 PP2A phosphorylation unclear human Sarcoma Rh1 Resveratrol Associated 3.0 (Low) 30066962
acc2260 ERK1 phosphorylation Thr202 human Sarcoma Rh1 Resveratrol Associated 3.0 (Low) 30066962
acc2261 ERK1 phosphorylation Tyr204 human Sarcoma Rh1 Resveratrol Associated 3.0 (Low) 30066962
acc2262 PP2A phosphorylation unclear human Colorectal Cancer HT29 Resveratrol Associated 3.0 (Low) 30066962
acc2263 ERK2 phosphorylation Thr185 human Colorectal Cancer HT29 Resveratrol Associated 3.0 (Low) 30066962
acc2264 ERK2 phosphorylation Tyr187 human Colorectal Cancer HT29 Resveratrol Associated 3.0 (Low) 30066962
acc2265 PP2A phosphorylation unclear human Cervical Cancer HeLa Resveratrol Associated 3.0 (Low) 30066962
acc2266 ERK1 phosphorylation Thr202 human Cervical Cancer HeLa Resveratrol Associated 3.0 (Low) 30066962
acc2267 ERK1 phosphorylation Tyr204 human Cervical Cancer HeLa Resveratrol Associated 3.0 (Low) 30066962
acc2268 ERK2 phosphorylation Thr185 human Cervical Cancer HeLa Resveratrol Associated 3.0 (Low) 30066962
acc2269 ERK2 phosphorylation Tyr187 human Cervical Cancer HeLa Resveratrol Associated 3.0 (Low) 30066962
acc2270 ERK2 phosphorylation Thr185 human Sarcoma Rh1 Resveratrol Associated 3.0 (Low) 30066962
acc2271 ERK2 phosphorylation Tyr187 human Sarcoma Rh1 Resveratrol Associated 3.0 (Low) 30066962
acc2272 PP2A phosphorylation unclear human Sarcoma Rh30 Resveratrol Associated 3.0 (Low) 30066962
acc2273 ERK1 phosphorylation Thr202 human Sarcoma Rh30 Resveratrol Associated 3.0 (Low) 30066962
acc2274 ERK1 phosphorylation Tyr204 human Sarcoma Rh30 Resveratrol Associated 3.0 (Low) 30066962
acc2275 ERK2 phosphorylation Thr185 human Sarcoma Rh30 Resveratrol Associated 3.0 (Low) 30066962
acc2276 ERK2 phosphorylation Tyr187 human Sarcoma Rh30 Resveratrol Associated 3.0 (Low) 30066962
acc2277 ERK1 phosphorylation Thr202 human Colorectal Cancer HT29 Resveratrol Associated 3.0 (Low) 30066962
acc2278 ERK1 phosphorylation Tyr204 human Colorectal Cancer HT29 Resveratrol Associated 3.0 (Low) 30066962
acc2279 RPS6 phosphorylation Ser235 human Breast Cancer SK-BR-3 Erlotinib Associated 4.0 (Moderate) 23552733
acc2280 RPS6 phosphorylation Ser236 human Breast Cancer SK-BR-3 Erlotinib Associated 4.0 (Moderate) 23552733
acc2281 RPS6 phosphorylation Ser235 human Breast Cancer HCC1954 Erlotinib + Pertuzumab Associated 4.0 (Moderate) 23552733
acc2282 RPS6 phosphorylation Ser236 human Breast Cancer HCC1954 Erlotinib + Pertuzumab Associated 4.0 (Moderate) 23552733
acc2283 RB phosphorylation Ser807 human Breast Cancer SK-BR-3 Erlotinib + Pertuzumab Associated 4.0 (Moderate) 23552733
acc2284 RB phosphorylation Ser811 human Breast Cancer SK-BR-3 Erlotinib + Pertuzumab Associated 4.0 (Moderate) 23552733
acc2285 RB phosphorylation Ser807 human Breast Cancer HCC1954 Erlotinib + Pertuzumab Associated 4.0 (Moderate) 23552733
acc2286 RB phosphorylation Ser811 human Breast Cancer HCC1954 Erlotinib + Pertuzumab Associated 4.0 (Moderate) 23552733
acc2287 RPS6 phosphorylation Ser235 human Breast Cancer SK-BR-3 Erlotinib + Trastuzumab Associated 4.0 (Moderate) 23552733
acc2288 RPS6 phosphorylation Ser236 human Breast Cancer SK-BR-3 Erlotinib + Trastuzumab Associated 4.0 (Moderate) 23552733
acc2289 RPS6 phosphorylation Ser235 human Breast Cancer HCC1954 Erlotinib + Trastuzumab Associated 4.0 (Moderate) 23552733
acc2290 RPS6 phosphorylation Ser236 human Breast Cancer HCC1954 Erlotinib + Trastuzumab Associated 4.0 (Moderate) 23552733
acc2291 RPS6 phosphorylation Ser235 human Breast Cancer HCC1954 Erlotinib Associated 4.0 (Moderate) 23552733
acc2292 RB phosphorylation Ser807 human Breast Cancer SK-BR-3 Erlotinib + Trastuzumab Associated 4.0 (Moderate) 23552733
acc2293 RB phosphorylation Ser811 human Breast Cancer SK-BR-3 Erlotinib + Trastuzumab Associated 4.0 (Moderate) 23552733
acc2294 RB phosphorylation Ser807 human Breast Cancer HCC1954 Erlotinib + Trastuzumab Associated 4.0 (Moderate) 23552733
acc2295 RB phosphorylation Ser811 human Breast Cancer HCC1954 Erlotinib + Trastuzumab Associated 4.0 (Moderate) 23552733
acc2296 RPS6 phosphorylation Ser236 human Breast Cancer HCC1954 Erlotinib Associated 4.0 (Moderate) 23552733
acc2297 RB phosphorylation Ser807 human Breast Cancer SK-BR-3 Erlotinib Associated 4.0 (Moderate) 23552733
acc2298 RB phosphorylation Ser811 human Breast Cancer SK-BR-3 Erlotinib Associated 4.0 (Moderate) 23552733
acc2299 RB phosphorylation Ser807 human Breast Cancer HCC1954 Erlotinib Associated 4.0 (Moderate) 23552733
acc2300 RB phosphorylation Ser811 human Breast Cancer HCC1954 Erlotinib Associated 4.0 (Moderate) 23552733